Health officials close to US Health Secretary Kennedy reportedly explored a ban of some widely used antidepressents, according to reports

This report about potential bans on widely used antidepressants by US health officials could significantly impact pharmaceutical companies involved, such as Eli Lilly and Pfizer. Regulatory actions like this can lead to volatility in related equities and may shift market sentiment towards the healthcare sector, particularly if investors perceive increased risk in the pharmaceutical space.